Abstracting and indexing is one of those quiet pieces of scientific infrastructure that most readers never think about, yet it determines nearly everything about how research travels. When a journal is indexed in a major database, every article it publishes is given a standardized bibliographic record, complete with authors, affiliations, keywords, and a persistent identifier, that can be retrieved by search engines, discovery platforms, and citation-tracking systems. Without that record, even excellent research risks becoming effectively invisible, buried in a journal that databases do not scan. Inclusion in the Science Citation Index Expanded, maintained as part of the Web of Science family of databases, is therefore a mark of editorial quality control and a practical guarantee that a journal’s output will be findable by the global research community.

The Science Citation Index Expanded has a long history as one of the core citation indexes in science. It covers thousands of journals across the natural sciences, engineering, medicine, and related disciplines, and its selection process is deliberately selective. Journals are evaluated on publishing standards, editorial rigor, international diversity of authorship and editorial boards, citation behavior, peer-review integrity, and the overall usefulness of the content to the research community. For a journal to be admitted, and then to remain, in the index requires sustained performance against those criteria. The Journal of Pharmaceutical Investigation’s entry into the index in 2021 marked the point at which its articles began accumulating formal citation records in the Web of Science ecosystem, the raw material from which metrics such as the Impact Factor are later computed.

That leads directly to the second and more widely discussed number: the 5.5 Impact Factor recorded for 2022. The Journal Impact Factor, produced annually in the Journal Citation Reports, is calculated by counting citations in a given year to items published in the journal during the two preceding years, then dividing by the number of citable items, typically articles and reviews, published in those same two years. A 2022 Impact Factor of 5.5 therefore reflects the average number of times that 2020 and 2021 articles in the journal were cited during 2022. It is a two-year citation window, which makes the metric sensitive to recent momentum and to fields where citation practices are fast-moving, as pharmaceutical research very much is.

Context matters enormously when interpreting that figure. A raw Impact Factor of 5.5 means little until it is compared against other journals in the same field, which is exactly what the category ranking provides. In Pharmacology and Pharmacy, a broad and heavily populated category with 278 indexed journals, the Journal of Pharmaceutical Investigation ranked 48th, placing it in the top quartile, or Q1. Quartile designations divide each category into four bands, and Q1 status is commonly used by libraries, funding agencies, and university evaluation committees as a shorthand for a journal sitting among the most influential quarter of titles in its discipline. For a journal that only entered the index in 2021, reaching Q1 within roughly two years of eligibility represents a notably rapid climb.

The mechanics behind that climb are worth understanding, because they illustrate how citation dynamics work in pharmaceutical research. Journals in this field benefit from several structural advantages: pharmaceutical science sits at the intersection of chemistry, biology, pharmacology, and clinical medicine, so articles tend to be cited from many neighboring disciplines rather than a single narrow community. Drug delivery technologies, formulation science, pharmacokinetics, and nanomedicine are all areas of intense global activity, and work published in these areas is frequently referenced in patents, review articles, and follow-up experimental studies. A journal that successfully attracts strong submissions in these active areas can accumulate citations quickly, and the two-year Impact Factor window rewards exactly that kind of momentum.

At the same time, the pharmaceutical research community has been vocal in recent years about the limits of single-number metrics, and any reading of the new figures should acknowledge those debates. The Impact Factor does not distinguish between a highly cited review and a routine research article, it can be influenced by a small number of exceptionally cited papers, and it says nothing about the methodological quality or reproducibility of individual studies. Initiatives such as the Declaration on Research Assessment, known as DORA, have urged institutions to move away from journal-level metrics when judging individual researchers, favoring article-level measures and qualitative expert review instead. The Journal of Pharmaceutical Investigation’s Q1 ranking is best understood as one signal among several, indicating broad visibility and citation uptake rather than certifying the quality of any specific paper.

For authors deciding where to submit, indexing status and quartile rankings still carry practical weight. Many national funding bodies and promotion committees maintain lists of acceptable journals built directly on Web of Science indexing and quartile positions, and some require publication in Q1 or Q2 titles for grant eligibility or degree completion. Indexing in the Science Citation Index Expanded also ensures that articles are preserved and discoverable through institutional libraries worldwide, which affects readership and, indirectly, future collaboration opportunities. In this sense, the journal’s documented indexing record and its 2022 metrics function as a form of infrastructure: they lower the friction between a published finding and the researcher who needs it.

What happens next will depend on the journal’s continued editorial performance. Impact Factors are recalculated every year, and quartile boundaries shift as competing journals rise and fall, so the 48th-of-278 position is a snapshot rather than a permanent achievement. Journals that sustain rigorous peer review, publish timely special issues in fast-moving areas such as biologics, drug delivery systems, and personalized pharmacotherapy, and maintain transparent editorial practices tend to hold their positions, while those that do not can slip quickly in a category as crowded as Pharmacology and Pharmacy. For now, the published record is clear: indexed in SciSearch since 2021, an Impact Factor of 5.5 in 2022, and a Q1 ranking within one of pharmacology’s largest and most competitive categories, a combination that firmly establishes the Journal of Pharmaceutical Investigation among the visible and influential outlets for pharmaceutical research.

Subject of Research: Indexing status and 2022 Impact Factor performance of the Journal of Pharmaceutical Investigation in the Science Citation Index Expanded

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, abstracting and indexing, Science Citation Index Expanded, SciSearch, Impact Factor, Journal Citation Reports, Pharmacology and Pharmacy, Q1 ranking, Web of Science, citation metrics, scholarly publishing, journal ranking

Abstracting and indexing is the infrastructure that makes scientific literature discoverable. When a journal is indexed in a database such as Science Citation Index Expanded, its articles are cataloged with standardized metadata, including author names, affiliations, abstracts, keywords, and cited references. This allows search engines and bibliographic databases to retrieve the work reliably when researchers query the literature. Without such indexing, even high-quality research risks becoming effectively invisible, buried in a journal that major discovery platforms do not cover. The Science Citation Index Expanded, maintained by Clarivate as part of the Web of Science Core Collection, is one of the most selective and widely used indexes in science, and inclusion in it signals that a journal has passed editorial and quality evaluations covering publishing standards, international diversity, peer-review rigor, and citation impact.

The 2022 Impact Factor of 5.5 reflects how often articles published in the journal during 2020 and 2021 were cited in 2022, averaged across the number of substantive items published in that window. Impact Factors are calculated annually from the citation data underlying the Journal Citation Reports, and they remain the single most quoted metric in journal evaluation despite ongoing debate about their limitations. A score of 5.5 places the Journal of Pharmaceutical Investigation comfortably above the median for pharmacology journals, a field that spans basic drug discovery, formulation science, pharmacokinetics, clinical pharmacology, and regulatory science. The Q1 designation, meaning the top quartile of the category, is a threshold that many institutions use when assessing whether a publication outlet meets quality expectations for faculty evaluation, grant reporting, and doctoral training requirements.

The journal’s rise through the rankings has been relatively rapid. Its inclusion in Science Citation Index Expanded dates to 2021, meaning that within roughly two years of entering the index it climbed into the upper quarter of a competitive category containing 278 journals. Pharmacology and Pharmacy is one of the most heavily populated categories in the Journal Citation Reports, encompassing everything from specialist translational titles to large general pharmacology journals, so a rank of 48 out of 278 represents a meaningful position rather than a marginal one. Analysts of scholarly publishing note that newly indexed journals often experience a citation lag, because articles published before indexing are not captured in Impact Factor calculations and it takes time for the journal to accumulate visibility in databases that researchers consult daily. Beating that lag and reaching Q1 quickly suggests strong citation performance for the recently published work that the metric does capture.

For the pharmaceutical research community, the journal’s visibility matters in practical terms. The Journal of Pharmaceutical Investigation publishes work on drug delivery systems, pharmacokinetics and pharmacodynamics, novel formulations, nanomedicine approaches, and investigative studies bridging laboratory findings and clinical application. Researchers in these areas compete for attention in a literature that grows by hundreds of thousands of articles each year. Indexing in SciSearch ensures that their papers appear in Web of Science searches, are linked through citation networks to related work, and are counted in the bibliometric profiles that individual scientists build over their careers. Citation counts drawn from indexed databases feed into h-index calculations, institutional rankings, and the evaluation criteria of major funding agencies, so the difference between an indexed and a non-indexed journal can directly affect a researcher’s professional trajectory.

The broader context is a scholarly publishing industry undergoing rapid change. Open access models, preprint servers, and alternative metrics have diversified how research is disseminated and assessed, yet established indexes such as Science Citation Index Expanded continue to function as gatekeepers of legitimacy. Clarivate applies a multi-stage evaluation to candidate journals, examining editorial consistency, peer-review integrity, the international composition of authorship and editorial boards, citation behavior, and adherence to publishing ethics standards. Journals that fail to meet these criteria are excluded, and those already indexed face periodic re-evaluation, with titles that decline in quality or engage in citation manipulation subject to delisting. In this environment, the Journal of Pharmaceutical Investigation’s sustained inclusion and its Q1 performance indicate that its editorial processes and citation record have withstood scrutiny from the field’s most influential bibliometric authority.

Librarians and research administrators pay close attention to these indicators when making collection and policy decisions. University libraries with constrained budgets rely on indexing status and quartile rankings to decide which subscriptions to maintain, while research offices frequently maintain lists of approved outlets for publication based on Journal Citation Reports quartiles. A Q1 pharmacology journal with a 5.5 Impact Factor is likely to appear on such lists, channeling submissions toward it and reinforcing the citation cycle that sustains its metrics. Critics of this feedback loop argue that it concentrates attention on already prominent journals and can disadvantage regional or emerging titles, but the practical reality for authors is that indexing and quartile remain decisive factors in where they send their manuscripts, particularly in applied fields where industry and regulatory audiences consult the indexed literature.

The journal’s metrics also carry weight internationally, particularly in Asia, where pharmaceutical sciences research output has expanded dramatically over the past two decades. The Journal of Pharmaceutical Investigation has historically served as a venue for research from pharmacology and pharmaceutics communities across Asia and beyond, and its strengthened bibliometric profile gives authors in these regions a high-visibility home for work that might otherwise migrate to Western-centric titles. Bibliometric studies have documented the growing share of global pharmaceutical research produced in countries such as South Korea, Japan, China, and India, and journals that combine regional roots with international indexing standards are well positioned to capture this expanding output. The 2022 figures suggest that the journal is successfully converting that growth into citation impact recognized at a global level.

Looking ahead, the journal’s trajectory will depend on maintaining the editorial quality and citation performance that underpin its current standing. Impact Factors fluctuate from year to year, and a single weak publication cycle can shift a journal’s quartile position in a category as densely packed as Pharmacology and Pharmacy. At the same time, the ongoing evolution of research assessment, including movements such as the Declaration on Research Assessment that encourage evaluation beyond a single metric, may gradually change how much weight the Impact Factor carries. For now, however, the combination of Science Citation Index Expanded coverage, a 5.5 Impact Factor, and a Q1 ranking gives the Journal of Pharmaceutical Investigation a strong position in the competitive market for pharmaceutical sciences research, and a clear signal to authors and readers about the visibility their work can expect to achieve.

Subject of Research: Abstracting and indexing status and citation impact of the Journal of Pharmaceutical Investigation

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, abstracting and indexing, Science Citation Index Expanded, SciSearch, Impact Factor, Journal Citation Reports, pharmacology, pharmacy, Q1 journal, Springer, bibliometrics, scholarly publishing